Región Metropolitana de Santiago
Este organismo compró $35.329.096.472 en 11.633 órdenes de compra , sobre todo en Medicamentos y productos farmacéuticos / Medicamentos anti infecciosos / Medicamentos antivirales y le compró principalmente a Sur Medical SpA.
238 meses con data · color por monto (sqrt scale)
| Año | Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sep | Oct | Nov | Dic | Total año |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
| $1367,1 M |
| 2025 | $2402,7 M |
| 2024 | $2107,2 M |
| 2023 | $2816,8 M |
| 2022 | $1338 M |
| 2021 | $1018,6 M |
| 2020 | $888,8 M |
| 2019 | $901,2 M |
| 2018 | $1471,2 M |
| 2017 | $786,1 M |
| 2016 | $14,2 mil M |
| 2015 | $919,8 M |
| 2014 | $428,8 M |
| 2013 | $340,8 M |
| 2012 | $359,5 M |
| 2011 | $701,4 M |
| 2010 | $913,7 M |
| 2009 | $590,7 M |
| 2008 | $571,8 M |
| 2007 | $1180,7 M |
| 2006 | $34,7 M |
238 períodos con data
Fuente: Agregaciones mensuales sobre OCs ingeridas
10 contrapartes
Fuente: Tabla top_contrapartes_comprador
| Código | Fecha | Proveedor | Estado | Monto |
|---|---|---|---|---|
| 2980-204-AG26 | 21-04-2026 | Inversiones Sb S.A. | Recepcion Conforme | $899.164 |
| 2980-175-AG26 | 21-04-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $1.806.424 |
| 2980-183-AG26 | 21-04-2026 | Laboratorios Richmond Chile Limitada | Recepcion Conforme | $328.440 |
| 2980-185-AG26 | 21-04-2026 | Novofarma Service S.A. | Recepcion Conforme | $4.760.095 |
| 2980-1-SE26 | 17-04-2026 | Oftomed Limitada | Recepcion Conforme | $91.146.930 |
| 2980-200-AG26 | 16-04-2026 | Bayer S.A. | Recepcion Conforme | $6.735.909 |
| 2980-194-AG26 | 16-04-2026 | Laboratorio Flex Pharma Chile Limitada | Recepcion Conforme | $3.564.288 |
| 2980-201-AG26 | 16-04-2026 | Pfizer Chile S.A. | Recepcion Conforme | $3.519.235 |
| 2980-191-AG26 | 15-04-2026 | Bayer S.A. | Recepcion Conforme | $6.735.909 |
| 2980-177-AG26 | 15-04-2026 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $6.669.902 |
| 2980-199-AG26 | 15-04-2026 | Clinical Market S.A. | Recepcion Conforme | $2.808.233 |
| 2980-174-AG26 | 15-04-2026 | Productos Farmoquimicos Roche Limitada | Recepcion Conforme | $5.814.097 |
| 2980-178-AG26 | 15-04-2026 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $5.002.427 |
| 2980-2-SE26 | 15-04-2026 | Ricardo Cid Tecnologias EIRL | Recepcion Conforme | $43.379.999 |
| 2980-176-AG26 | 15-04-2026 | Dr. Reddys Laboratories Chile SpA | Recepcion Conforme | $5.482.092 |
| 2980-173-AG26 | 07-04-2026 | Novartis Chile S.A. | Recepcion Conforme | $4.285.428 |
| 2980-160-AG26 | 06-04-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $547.352 |
| 2980-164-AG26 | 06-04-2026 | Novofarma Service S.A. | Recepcion Conforme | $2.380.048 |
| 2980-165-AG26 | 06-04-2026 | Synthon Chile Limitada | Recepcion Conforme | $1.342.320 |
| 2980-169-AG26 | 06-04-2026 | Novofarma Service S.A. | Recepcion Conforme | $2.380.048 |
| 2980-171-AG26 | 06-04-2026 | Pfizer Chile S.A. | Recepcion Conforme | $5.000.349 |
| 2980-161-AG26 | 06-04-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $547.352 |
| 2980-172-AG26 | 06-04-2026 | Pfizer Chile S.A. | Recepcion Conforme | $292.740 |
| 2980-162-AG26 | 06-04-2026 | Novartis Chile S.A. | Recepcion Conforme | $2.374.071 |
| 2980-168-AG26 | 06-04-2026 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $896.457 |
| 2980-170-AG26 | 02-04-2026 | Astrazeneca S.A. | Recepcion Conforme | $5.634.679 |
| 2980-167-AG26 | 26-03-2026 | Pro Sales Diego Torneria EIRL | Recepcion Conforme | $769.930 |
| 2980-166-AG26 | 25-03-2026 | Sociedad Comercial y de Inversiones Corp Premier Limitada | Recepcion Conforme | $1.643.771 |
| 2980-163-AG26 | 24-03-2026 | Pfizer Chile S.A. | Aceptada | $3.519.235 |
| 2980-132-AG26 | 23-03-2026 | Novofarma Service S.A. | Recepcion Conforme | $4.760.095 |
